CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
Part of Cancer, Kidney & urinary clinical trials.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with advanced or unresectable clear cell kidney cancer that has grown or spread after at least two prior treatments (including immunotherapy and a targeted drug)
- Your tumor tissue must show CD70 protein expression (a marker the CAR-T cells target)
- At least one measurable tumor visible on imaging
- Good overall health status (Karnofsky Performance Status score ≥70%, meaning you can manage most daily activities)
- Normal or near-normal blood counts, liver, kidney, heart, and lung function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
This trial is testing a new type of cell therapy for advanced kidney cancer that has not responded to standard treatments. The therapy takes your own immune cells, modifies them to target a protein called CD70 on the cancer cells, and gives them back to you to help fight the cancer.
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Hear when a new Unresectable or Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.